About Anuh Pharma Limited
Data last updated:
Anuh Pharma Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 19 February 1960 and has been in existence for over 66 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24230MH1960PLC011586. Its GSTIN is 27AAACA4478P1Z5 (Maharashtra). The company holds 2 GST registrations, of which 1 is active. Its shares are listed on BSE: 506260 and NSE: ANUHPHR.
The company has an authorised share capital of ₹51 Cr and a paid-up capital of ₹50.11 Cr. It is led by directors including Ritesh Bipin Shah (Managing Director) and Vivek Bipin Shah (Managing Director).
Its last annual general meeting (AGM) was held on 22 August 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at A 3 Shiv Sagar Estatedr Annie Besant Road, Mumbai, Maharashtra, India – 400018.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹771.66 Cr, a growth of 16.7% compared to the previous year. For the same year it recorded a net profit of ₹36.33 Cr (net margin 4.7%) and EBITDA of ₹62.21 Cr (EBITDA margin 8.1%). The net worth stands at ₹352.22 Cr (up 8% YoY). Total assets are valued at ₹354.42 Cr (up 4.6% YoY).
The company has about 212 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Anuh Pharma and SK Age Exports. As per MCA filings, the company has open charges of ₹95 Cr and satisfied charges of ₹112.11 Cr on record. Court records list 17 cases involving the company, including 14 filed by the company and 3 filed against it; 7 cases are pending. The company has 11 deals on record (11 market trades); the latest was in September 2020. Its 9 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Tagoor Laboratories Private Limited with revenue of ₹719.28 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website anuhpharma.com.
Company details
CIN history
Anuh Pharma has one previous CIN (Corporate Identification Number): U24230MH1960PLC011586. The current CIN is L24230MH1960PLC011586, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230MH1960PLC011586 | Current |
| U24230MH1960PLC011586 | Previous |
Contact details
Anuh Pharma Limited's registered office is in Mumbai, Maharashtra. Its website is anuhpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressA 3 Shiv Sagar Estatedr Annie Besant Road, Mumbai, Maharashtra, India – 400018
- IndustryPharma, API Manufacturers
To see the full contact details of Anuh Pharma Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Anuh Pharma operates two associated brands: Anuh Pharma and SK Age Exports. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| APIs, bulk drugs, and formulations are manufactured and traded. | anuhpharma.com | |
| International goods exports are managed from Mumbai, India. | skageexports.com |
Business activity
The main business activity of Anuh Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Anuh Pharma Limited, buy the company report.
Financials of Anuh Pharma Limited
FY 2025-26 filings availableAnuh Pharma Limited reported revenue of ₹771.66 Cr (up 16.7% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 772 | 662 | 647 | 527 | 487 | 432 | 307 |
| Revenue growth | +16.7% | +2.2% | +22.7% | +8.4% | +12.7% | +40.7% | - |
| EBITDA | 62.21 | 61.52 | 75.75 | 51.81 | 47.47 | 45.12 | 23.24 |
| EBITDA margin | +8.1% | +9.3% | +11.7% | +9.8% | +9.8% | +10.5% | +7.6% |
| Profit before tax | 54.23 | 61.00 | 78.31 | 47.47 | 39.13 | 38.55 | 19.16 |
| Net profit | 36.33 | 37.62 | 51.89 | 32.94 | 28.60 | 22.49 | 13.25 |
| Net profit margin | +4.7% | +5.7% | +8.0% | +6.2% | +5.9% | +5.2% | +4.3% |
| EPS (₹) | 4.10 | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 | 5.71 |
| Balance sheet | |||||||
| Total assets | 354 | 339 | 295 | 244 | 220 | 206 | 209 |
| Net worth | 352 | 326 | 291 | 241 | 214 | 191 | 162 |
| Total debt | 0.06 | 10.89 | 2.69 | 0.91 | 4.22 | 13.68 | 45.15 |
| Cash & bank | 8.30 | 19.74 | 8.37 | 6.65 | 15.95 | 20.09 | 2.52 |
| Net working capital | 204 | 155 | 133 | 95.19 | 110 | 101 | 39.47 |
| Cash flow | |||||||
| Cash from operations | (3.01) | 37.12 | 12.93 | 53.90 | 28.86 | (18.73) | 48.93 |
| Cash from investing | 17.84 | (19.91) | 0.92 | (43.48) | (7.82) | 52.20 | (76.53) |
| Cash from financing | (26.33) | (4.86) | (8.57) | (12.29) | (19.45) | (33.12) | 22.17 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 194 | 202 | 197 | 186 | 186 | 198 | 160 | 166 |
| Revenue growth (YoY) | +3.9% | +2.0% | +23.6% | +12.0% | +35.2% | - | - | - |
| Other income | 3.08 | (1.25) | 1.79 | 0.98 | 3.39 | 1.40 | 0.94 | 3.40 |
| Total expenses | 178 | 182 | 178 | 174 | 176 | 179 | 145 | 149 |
| EBITDA | 16.29 | 19.89 | 19.12 | 11.88 | 10.29 | 18.67 | 14.79 | 16.88 |
| EBITDA margin | +8.4% | +9.8% | +9.7% | +6.4% | +5.5% | +9.4% | +9.3% | +10.2% |
| Depreciation | 2.43 | 3.00 | 3.00 | 2.86 | 2.52 | 2.76 | 2.18 | 1.92 |
| Interest | 0.00 | 0.11 | 0.08 | 0.08 | 0.21 | 0.03 | 0.28 | 0.16 |
| Profit before tax | 16.94 | 15.53 | 17.83 | 9.92 | 10.95 | 17.28 | 13.27 | 18.20 |
| Tax | 5.50 | 3.84 | 4.37 | 2.31 | 2.65 | 4.83 | 2.92 | 3.15 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 194 | 202 | 197 | 186 | 186 | 198 | 160 | 166 |
| Revenue growth (YoY) | +3.9% | +2.0% | +23.6% | +12.0% | +35.2% | - | - | - |
| Other income | 3.08 | (1.25) | 1.79 | 0.98 | 3.39 | 1.40 | 0.94 | 3.40 |
| Total expenses | 178 | 182 | 178 | 174 | 176 | 179 | 145 | 149 |
| EBITDA | 16.29 | 19.89 | 19.12 | 11.88 | 10.29 | 18.67 | 14.79 | 16.88 |
| EBITDA margin | +8.4% | +9.8% | +9.7% | +6.4% | +5.5% | +9.4% | +9.3% | +10.2% |
| Depreciation | 2.43 | 3.00 | 3.00 | 2.86 | 2.52 | 2.76 | 2.18 | 1.92 |
| Interest | 0.00 | 0.11 | 0.08 | 0.08 | 0.21 | 0.03 | 0.28 | 0.16 |
| Profit before tax | 16.94 | 15.53 | 17.83 | 9.92 | 10.95 | 17.28 | 13.27 | 18.20 |
| Tax | 5.50 | 3.84 | 4.37 | 2.31 | 2.65 | 4.83 | 2.92 | 3.15 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 772 | 662 | 647 | 527 | 487 | 432 | 307 |
| Revenue growth | +16.7% | +2.2% | +22.7% | +8.4% | +12.7% | +40.7% | - |
| Other income | 4.36 | 9.46 | 12.10 | 6.11 | 5.20 | 10.54 | 4.21 |
| Total expenses | 709 | 600 | 571 | 476 | 439 | 387 | 284 |
| Employee cost | 26.30 | 23.04 | 19.39 | 17.15 | 15.10 | 14.29 | 13.36 |
| EBITDA | 62.21 | 61.52 | 75.75 | 51.81 | 47.47 | 45.12 | 23.24 |
| EBITDA margin | +8.1% | +9.3% | +11.7% | +9.8% | +9.8% | +10.5% | +7.6% |
| Depreciation | 11.38 | 8.74 | 8.58 | 9.70 | 11.96 | 15.08 | 7.03 |
| Interest | 0.96 | 1.24 | 0.96 | 0.75 | 1.58 | 2.03 | 1.26 |
| Profit before tax | 54.23 | 61.00 | 78.31 | 47.47 | 39.13 | 38.55 | 19.16 |
| Tax | 13.17 | 13.65 | 18.25 | 11.29 | 8.56 | 10.12 | 4.85 |
| Net profit | 36.33 | 37.62 | 51.89 | 32.94 | 28.60 | 22.49 | 13.25 |
| Net profit margin | +4.7% | +5.7% | +8.0% | +6.2% | +5.9% | +5.2% | +4.3% |
| EPS (₹) | 4.10 | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 | 5.71 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 50.11 | 25.06 | 25.06 | 25.06 | 25.06 | 25.06 | 12.53 |
| Reserves & surplus | 302 | 301 | 266 | 216 | 189 | 166 | 150 |
| Shareholders' funds (net worth) | 352 | 326 | 291 | 241 | 214 | 191 | 162 |
| Secured loans | 0.00 | 10.50 | 2.01 | 0.00 | 3.11 | 13.60 | 44.56 |
| Unsecured loans | 0.06 | 0.39 | 0.68 | 0.91 | 1.11 | 0.08 | 0.59 |
| Total debt | 0.06 | 10.89 | 2.69 | 0.91 | 4.22 | 13.68 | 45.15 |
| Total liabilities | 354 | 339 | 295 | 244 | 220 | 206 | 209 |
| Assets | |||||||
| Gross block | 129 | 120 | 103 | 99.91 | 99.18 | 97.93 | 96.38 |
| Net block | 56.62 | 58.21 | 48.94 | 52.81 | 61.43 | 71.42 | 84.04 |
| Capital work in progress | 0.00 | 0.27 | 0.45 | 0.00 | 0.10 | 0.00 | 0.00 |
| Investments | 84.44 | 106 | 96.77 | 90.83 | 42.68 | 31.39 | 79.56 |
| Inventories | 148 | 74.48 | 75.40 | 72.64 | 79.92 | 81.43 | 61.49 |
| Sundry debtors | 239 | 216 | 190 | 171 | 136 | 107 | 81.03 |
| Cash & bank balances | 8.30 | 19.74 | 8.37 | 6.65 | 15.95 | 20.09 | 2.52 |
| Loans & advances | 11.77 | 12.23 | 9.76 | 5.94 | 5.64 | 18.34 | 12.06 |
| Total current assets | 406 | 322 | 283 | 256 | 237 | 227 | 157 |
| Total current liabilities | 203 | 168 | 150 | 161 | 128 | 126 | 118 |
| Net working capital | 204 | 155 | 133 | 95.19 | 110 | 101 | 39.47 |
| Total assets | 354 | 339 | 295 | 244 | 220 | 206 | 209 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 19.56 | 7.20 | 1.93 | 3.80 | 2.20 | 1.85 | 7.27 |
| Net cash from operating activities | (3.01) | 37.12 | 12.93 | 53.90 | 28.86 | (18.73) | 48.93 |
| Net cash from investing activities | 17.84 | (19.91) | 0.92 | (43.48) | (7.82) | 52.20 | (76.53) |
| Net cash from financing activities | (26.33) | (4.86) | (8.57) | (12.29) | (19.45) | (33.12) | 22.17 |
| Net change in cash | (11.50) | 12.36 | 5.27 | (1.87) | 1.60 | 0.35 | (5.43) |
| Closing cash | 8.30 | 19.74 | 8.37 | 6.65 | 15.95 | 20.09 | 2.52 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +16.7% | +2.2% | +22.7% | +8.4% | +12.7% | +40.7% | - |
| EBITDA growth | +1.1% | -18.8% | +46.2% | +9.1% | +5.2% | +94.2% | - |
| PBT growth | -11.1% | -22.1% | +65.0% | +21.3% | +1.5% | +101.2% | -40.9% |
| Net income growth | -3.4% | -27.5% | +57.5% | +15.2% | +27.2% | +69.7% | - |
| Revenue CAGR (3Y) | +13.5% | +10.8% | +14.4% | +19.8% | +14.9% | +22.0% | +14.2% |
| EBITDA CAGR (3Y) | +6.3% | +9.0% | +18.9% | +30.6% | +16.6% | +35.0% | +0.9% |
| Profitability & leverage | |||||||
| Net income margin | +5.3% | +7.2% | +9.3% | +6.9% | +6.3% | +6.6% | +4.7% |
| Return on capital employed | +15.9% | +17.2% | +25.4% | +20.8% | +19.1% | +15.7% | +10.8% |
| Return on net worth | +12.1% | +12.2% | +19.5% | +15.9% | +15.1% | +12.8% | +8.8% |
| Debt / equity | 0.02 | 0.02 | 0.01 | 0.01 | 0.04 | 0.17 | 0.15 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 1.89 | 2.35 | 1.43 | 1.78 | 4.45 | 6.76 | 7.77 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 6.19 | 5.93 | 6.38 | 5.30 | 4.94 | 4.45 | 5.00 |
| Inventory turnover | 6.94 | 8.83 | 8.74 | 6.92 | 6.03 | 6.04 | 5.88 |
| Debtors turnover | 3.40 | 3.26 | 3.58 | 3.44 | 4.01 | 4.60 | 3.95 |
| EPS (₹) | 4.10 | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 | 5.71 |
| Dividend per share (₹) | 1.50 | 1.50 | 2.50 | 2.00 | 1.75 | 1.50 | 2.75 |
| Book value per share (₹) | 35.14 | 65.06 | 58.11 | 48.14 | 42.66 | 38.04 | 64.74 |
To see the full year-wise statements and ratios of Anuh Pharma Limited, buy the company report.
Board of directors of Anuh Pharma Limited
Anuh Pharma has 12 current directors and 13 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Arun Lalchand Todarwal Also directs: Arun Todarwal & Associates LLP, Arun Todarwal & Co LLP, Laxmi Organic Industries Limited and 5 more | Director | 24 Oct 2008 | 17 Years 11 Months | Current |
| Bharat Nemchand Shah | Director | 29 Oct 1980 | 45 Years 11 Months | Current |
| Ritesh Bipin Shah Also directs: S Kant Healthcare Limited | Managing Director | 09 Aug 2016 | 10 Years 2 Months | Current |
| Samir Jayantilal Shah Also directs: Eskay Iodine Private Limited, Chaitanya Life Science Private Limited, Skites India LLP and 5 more | Director | 09 Aug 2016 | 10 Years 2 Months | Current |
| Ketan Lalit Shah Also directs: Eskay Iodine Private Limited, Chaitanya Life Science Private Limited, L P Shah Holdings and Trades LLP and 2 more | Director | 09 Aug 2016 | 10 Years 2 Months | Current |
| Bipin Nemchand Shah | Director | 01 Apr 2009 | 17 Years 6 Months | Current |
Peer comparison
Anuh Pharma Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Anuh Pharma Limited this company | ₹771.66 Cr (FY 2026) | 16.7% | 212 | Mumbai, Maharashtra, India | ||
| Tagoor Laboratories Private Limited | ₹719.28 Cr (FY 2022) | 55.0% | Andhra Pradesh, India | |||
| Optimus Drugs Private Limited | ₹713.55 Cr (FY 2024) | -41.0% | Hyderabad, Telangana, India | |||
| Supriya Lifescience Limited Listed | ₹706.3 Cr (FY 2025) | 22.0% | Mumbai, Maharashtra, India | |||
| Dasami Lab Private Limited | ₹694.39 Cr (FY 2025) | 22.0% | Chityal, Telangana, India | |||
| RPG Life Sciences Limited Listed | ₹666.11 Cr (FY 2025) | 13.0% | Mumbai, Maharashtra, India | |||
| Ami Lifesciences Pvt Ltd | ₹659.86 Cr (FY 2025) | 20.0% | Vadodara, Gujarat, India | |||
| Nosch Labs Private Limited | ₹643.87 Cr (FY 2025) | 5.0% | Hyderabad, Telangana, India | |||
| Ind Swift Laboratories Limited Listed | ₹643.09 Cr (FY 2025) | -64.0% | Chandigarh, India | |||
| Amoli Organics Private Limited | ₹641.59 Cr (FY 2022) | 7.0% | Valsad, Gujarat, India |
To see the full peer comparison of Anuh Pharma Limited, buy the company report.
Auditor
Anuh Pharma Limited is audited by JAYANTILAL THAKKAR & CO. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| JAYANTILAL THAKKAR & CO. | FY 2023 | 104133W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 71.80%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 28.20%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 71.80% | 71.80% | 71.80% | 71.80% |
| Public | 28.20% | 28.20% | 28.20% | 28.20% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 02 Feb 2017 | 100082262 | Hdfc Bank Limited | ₹95 Cr | Open | |
| 06 Jan 2007 | 10038218 | Bank of India | ₹65 Cr | Satisfied | |
| 20 Mar 1999 | 90186656 | Bank of India | ₹25 Lakh | Satisfied | |
| 23 Apr 1997 | 90186448 | Bank of India | ₹20 Lakh | Satisfied | |
| 19 Jul 1995 | 90184014 | Bank of India | ₹45 Cr | Satisfied |
To see the full charge records of Anuh Pharma Limited, buy the company report.
Total charge records: 11 View all charges
Deals & funding
Anuh Pharma Limited has 11 deals on record (11 market trades); the latest was in September 2020.
Deals on record (5 of 11)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2020 | Market trade | ₹2.87 Cr | Seller: an individual |
| May 2015 | Market trade | ₹19.77 Cr | Buyer: 2 individuals Seller: L P Shah Holdings and Trades LLP |
| Aug 2010 | Market trade | ₹1.79 Cr | Buyer: an individual Seller: an individual |
| Nov 2009 | Market trade | ₹1.02 Cr | Buyer: an individual |
| Sep 2008 | Market trade | ₹1.26 Cr | Buyer: L P Shah Holding Trades Pvt Ltd Seller: an individual |
To see the full deal history of Anuh Pharma Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Anuh Pharma Limited has 17 court cases on record: 14 filed by Anuh Pharma, 3 filed against it. 7 cases are pending and 10 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 13 | 3 | 5 |
| High courts | 4 | 0 | 2 |
Cases on record (5 of 17)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai City Civil Court, Maharashtra | Commercial matter | Filed by the company against Cian Healthcare Limited and 6 others | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summary Cases) | Filed by the company against Kartik Turkhia Proprietor of Ms Indo Pharma | Pending |
| High Court | Writ petition | Filed by the company against Union of India and 7 others | Pending |
| District court, Thane, Maharashtra | Court case (M.A.C.P.) | Filed against the company by an individual | Pending |
| District court, Thane, Maharashtra | Court case (M.A.C.P.) | Filed against the company by an individual | Pending |
To see the full case history of Anuh Pharma Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Anuh Pharma Limited was last rated by Icra on 19 Aug 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Icra | 19 Aug 2021 |
To see the full credit ratings and regulatory alerts of Anuh Pharma Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Anuh Pharma Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Anuh Pharma Limited has a workforce of 212 employees on its EPFO records as of Apr 08, 2024, across 1 active EPFO establishment.
GST
Anuh Pharma has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACA4478P1Z5 | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Anuh Pharma Limited, buy the company report.
Recent activity
Anuh Pharma Limited has 32 board changes on record since 1980: 22 appointments and 10 cessations. The latest: Sandeep Madhusudan Joshi ceased to be Director on 21 Aug 2024.
52 earlier events are in the company report.
News
Frequently asked questions
Anuh Pharma is an active public limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 19 February 1960 (66+ years old) and is registered under CIN L24230MH1960PLC011586. Listed on BSE: 506260 and NSE: ANUHPHR.
Anuh Pharma reported revenue of ₹771.66 Cr for FY 2025-26 (up 16.7% YoY) based on standalone financials.
Anuh Pharma has 12 current directors:
- Ritesh Bipin Shah - Managing Director
- Vivek Bipin Shah - Managing Director
- Arun Lalchand Todarwal - Director
- Bharat Nemchand Shah - Director
- Samir Jayantilal Shah - Director
- Ketan Lalit Shah - Director
- Bipin Nemchand Shah - Director
- Mita Dixit - Director
- Harmanbhai Tulshibhai Patel - Director
- Pradeep Hari Thakur - Director
- Siddharth Shah Jasvantlal - Director
- Gaurav Satish Shah - Director
The latest financial statements of Anuh Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 22 August 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Anuh Pharma is 27AAACA4478P1Z5, registered in Maharashtra. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Anuh Pharma is L24230MH1960PLC011586. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Anuh Pharma is listed on both BSE (code: 506260) and NSE (symbol: ANUHPHR).
Anuh Pharma has 17 court cases on record: 14 filed by the company and 3 filed against it. 7 are pending. Most are in the district courts.
Anuh Pharma was incorporated on 19 February 1960, making it 66+ years old. It is registered with the Registrar of Companies, Mumbai.
Anuh Pharma has 11 deals on record (11 market trades); the latest was in September 2020.
The peers of Anuh Pharma by revenue are Tagoor Laboratories Private Limited, Optimus Drugs Private Limited, Supriya Lifescience Limited, Dasami Lab Private Limited, RPG Life Sciences Limited and 4 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).